| 0.9715 0.028 (2.99%) | 01-13 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.39 | 1-year : | 1.63 |
| Resists | First : | 1.19 | Second : | 1.39 |
| Pivot price | 0.94  |
|||
| Supports | First : | 0.86 | Second : | 0.71 |
| MAs | MA(5) : | 0.94 |
MA(20) : | 0.96 |
| MA(100) : | 1.33 |
MA(250) : | 3.44 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 40.1 |
D(3) : | 34.8 |
| RSI | RSI(14): 46.7 |
|||
| 52-week | High : | 14 | Low : | 0.81 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ LNAI ] has closed below upper band by 36.0%. Bollinger Bands are 70.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 8 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1 - 1 | 1 - 1.01 |
| Low: | 0.9 - 0.9 | 0.9 - 0.91 |
| Close: | 0.96 - 0.97 | 0.97 - 0.98 |
A company rebranding from Renovaro, focusing on AI-powered therapeutics and biodefense, with “Neurotoxicity Intelligence Technology” in development.
Thu, 18 Dec 2025
AI drug startup in Parkinson's race draws attention as pharma talks heat up - Stock Titan
Thu, 18 Dec 2025
Lunai Bioworks (NASDAQ: LNAI) Featured in International Business Times as AI Partnership Talks Advance - PR Newswire
Tue, 25 Nov 2025
Lunai Bioworks stock soars after securing first licensing deal for cancer therapy - MSN
Tue, 25 Nov 2025
Lunai Bioworks Secures $3.1M in Private Placement - TipRanks
Tue, 25 Nov 2025
Lunai Bioworks stock soars after securing first licensing deal for cancer therapy - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 23 (M) |
| Shares Float | 14 (M) |
| Held by Insiders | 39.5 (%) |
| Held by Institutions | 10.7 (%) |
| Shares Short | 777 (K) |
| Shares Short P.Month | 1,140 (K) |
| EPS | -7.91 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.57 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -14.9 % |
| Return on Equity (ttm) | -308.1 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.65 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -7 (M) |
| Levered Free Cash Flow | -6 (M) |
| PE Ratio | -0.13 |
| PEG Ratio | 0 |
| Price to Book value | -1.74 |
| Price to Sales | 0 |
| Price to Cash Flow | -3.16 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|